## Edgar Filing: Varadan Anand - Form 4

Varadan An Form 4	and									
June 25, 20	18									
FORM	NT	PPROVAL								
Washington, D.C. 20549								N OMB Number:	3235-0287	
Check the if no lon subject the Section Form 4 Form 5	so <b>STATEN</b> 16. or	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							January 31, 2005 average urs per . 0.5	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
1. Name and A Varadan A	2. Issuer Name <b>and</b> Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer						
			Karyop [KPTI]	bharm The	erapeutic	es Inc.	(Check all applicable)			
(Last) (First) (Middle) C/O KARYOPHARM			3. Date of Earliest Transaction (Month/Day/Year) 06/22/2018			Director 10% Owner X Officer (give title Other (specify below) below) EVP, Chief Commercial Officer				
THERAPE	UTICS INC.									
Filed(Month/Day/Year) Applicable Line _X_Form filed							Applicable Line) _X_ Form filed by	oint/Group Filing(Check One Reporting Person More than One Reporting		
85 WELLS	AVE, MA 02459	J					Person			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	e Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	Disposed	l (A) or l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(D) Price	(mout, 5 and 4)			
Reminder: Re	port on a separate line	e for each cl	ass of sec	urities bene	-	-	-			
					infor requi	mation con red to resp	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amoun
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securiti

number.

## Edgar Filing: Varadan Anand - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		/Year)	(Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou Numl Share
Nonstatutory Stock Option (right to buy)	\$ 18.68	06/22/2018		А	150,000	<u>(1)</u>	06/21/2028	Common Stock	150.

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
	Director	10% Owner	Officer	Other		
Varadan Anand C/O KARYOPHARM THERAPEUTICS INC. 85 WELLS AVE, MA 02459			EVP, Chief Commercial Officer			
Signatures						
/s/ Christopher B. Primiano, Attorney-in-Fact fo Varadan	or Anand		06/25/2018			
**Signature of Reporting Person			Date			

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was granted on June 22, 2018. The shares underlying this option vest as to 25% of the shares on June 22, 2019, with the remaining 75% vesting in 36 equal monthly installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.